BlackRock Global Dividend Fund posted returns of -4.66% (Institutional shares) and -4.64% (Investor A shares, without sales ...

Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...

This is centered on its hotly popular drug Wegovy. Before market open, Novo Nordisk announced the launch of its NovoCare Pharmacy, a direct-to-patient delivery service for its best-selling Wegovy ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy ...

To provide a return, net of fees, higher than that provided by the FTSE World Europe Ex UK Index over the long term (at least five years). At least 70% of the Fund is invested in shares of companies ...

Relx PLC (LON:REL) recuou 2,56%, ou 100,00 pontos, terminando em 3.805,00, e Persimmon PLC (LON:PSN) diminuiu 2,53%, ou 30,50 pontos, para 1.175,00. As ações em alta superaram os papéis com resultados ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims & Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

O pacote para o Brasil ainda é segredo. Quando chegar ao mercado, o novo WR-V será posicionado na base de SUVs da Honda no Brasil e, portanto, ficará abaixo do HR-V. Autoesporte apurou que os preços ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that had ...